Jacob D Soumerai
Overview
Explore the profile of Jacob D Soumerai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
1013
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Treon S, Kotton C, Park D, Moranzoni G, Lemvigh C, Gathe Jr J, et al.
Front Immunol
. 2025 Feb;
15:1369619.
PMID: 39906744
Background: Cytokine release triggered by a hyperactive immune response is thought to contribute to severe acute respiratory syndrome coronavirus 2019 (SARS-CoV-2)-related respiratory failure. Bruton tyrosine kinase (BTK) is involved in...
2.
Toulmin S, Nazir H, Abramson J, Soumerai J, Freeman E
Leuk Lymphoma
. 2025 Jan;
1-3.
PMID: 39862062
No abstract available.
3.
Soumerai J, Barrientos J, Barrientos J, Ahn I, Ahn I, Coombs C, et al.
Blood Adv
. 2024 Nov;
9(5):1213-1229.
PMID: 39561376
Over the past decade, treatment recommendations for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have shifted from traditional chemoimmunotherapy to targeted therapies. Multiple new therapies are...
4.
Kaulen L, Karschnia P, Doubrovinskaia S, Abramson J, Martinez-Lage M, Shankar G, et al.
Am J Hematol
. 2024 Oct;
99(12):2411-2415.
PMID: 39440883
Lymphomatous infiltration of the peripheral nervous system (PNS), termed neurolymphomatosis, represents a distinct extranodal non-Hodgkin lymphoma variant with dismal outcome. CD19-directed chimeric antigen receptor (CD19-CAR) T-cell therapy has emerged as...
5.
Kumar A, Soumerai J, Soumerai J, Abramson J, Barnes J, Caron P, et al.
Blood
. 2024 Oct;
145(5):497-507.
PMID: 39437708
TP53-mutant mantle cell lymphoma (MCL) is associated with poor survival outcomes with standard chemoimmunotherapy. We conducted a multicenter, phase 2 study of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in untreated patients...
6.
Soumerai J, Yousif Z, Gift T, Desai R, Huynh L, Ye M, et al.
Blood Adv
. 2024 Jun;
8(16):4239-4249.
PMID: 38904477
Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) can develop hypogammaglobulinemia, a form of secondary immune deficiency (SID), from the disease and treatments. Patients with hypogammaglobulinemia with recurrent...
7.
Soumerai J, Diefenbach C, Jagadeesh D, Asch A, Kumar A, Tsai M, et al.
Br J Haematol
. 2024 Mar;
204(5):1762-1770.
PMID: 38500476
The combination of the phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor zandelisib with the Bruton's tyrosine kinase (BTK) inhibitor zanubrutinib was hypothesized to be synergistic and prevent resistance to single-agent therapy. This...
8.
Nemec R, Scherrer-Crosbie M, Abramson J, Redd R, Gilman H, Ho T, et al.
Leuk Lymphoma
. 2024 Feb;
65(6):783-788.
PMID: 38380861
STOP-CA was a multicenter, double-blind, randomized, placebo-controlled trial comparing atorvastatin to placebo in treatment-naïve lymphoma patients receiving anthracycline-based chemotherapy. We performed a preplanned subgroup to analyze the impact of atorvastatin...
9.
Lei M, Sorial M, Lou U, Yu M, Medrano A, Ford J, et al.
Leuk Lymphoma
. 2024 Jan;
65(5):653-659.
PMID: 38293753
Venetoclax-obinutuzumab (Ven-O) is frequently administered off-label in relapsed/refractory (r/r) CLL/SLL where venetoclax-rituximab is the approved regimen. We conducted this retrospective, real-world study to evaluate Ven-O in r/r CLL/SLL. Between 7/2019...
10.
Redd R, Ford J, Lei M, Abramson J, Soumerai J
Leuk Lymphoma
. 2023 Oct;
64(14):2296-2305.
PMID: 37798861
BTK inhibitors (BTKi) are highly effective in B-cell malignancies. Acalabrutinib and zanubrutinib have exhibited favorable safety profiles when compared with ibrutinib. We identified all published/presented randomized trials comparing a second-generation...